Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR446523 |
Synonyms | |
Therapy Description |
SAR446523 is an IgG1 anti-GPRC5D antibody, which binds to GPRC5D on tumor cells and potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and anti-tumor activity (Cancer Res (2024) 84 (6_Supplement): 2727). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR446523 | SAR446523 is an IgG1 anti-GPRC5D antibody, which binds to GPRC5D on tumor cells and potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and anti-tumor activity (Cancer Res (2024) 84 (6_Supplement): 2727). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06630806 | Phase Ib/II | SAR446523 | A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma | Recruiting | AUS | 0 |